Loading...
Methicillin-resistant Staphylococcus aureus (MRSA) accounts for 10% to 40% of nosocomial pneumonias. Previous trials have suggested that linezolid is noninferior to vancomycin — the current standard therapy — with respect to outcome. However, those studies used a fixed dose of vancomycin that might not have been optimal.
To correct for this limitation, researchers conducted a phase IV, randomized, double-blind, multinational trial comparing intravenous linezolid (600 mg every 12 hours) with vancomycin (15 mg/kg every 12 hours, with dosage adjustment based on serum vancomycin levels and renal impairment) among hospitalized adults with nosocomially acquired, laboratory-confirmed MRSA pneumonia. The study was funded by the manufacturer of linez…